Sequence Conservation and Antibody Cross-Recognition of Clade B Human Immunodeficiency Virus (HIV) Type 1 Tat Protein in HIV-1-Infected Italians, Ugandans, and South Africans

Journal of Infectious Diseases

Volumn 188, Issue 8, 2003, Pages 1171-1180

  Buttò, Stefano ^a   Fiorelli, Valeria ^a   Tripiciano, Antonella ^a   Ruiz Alvarez, Maria J ^a   Scoglio, Arianna ^a   Ensoli, Fabrizio ^a   Ciccozzi, Massimo ^a   Collacchi, Barbara ^a   Sabbatucci, Michela ^a   Cafaro, Aurelio ^a   Guzmán, Carlos A ^c   Borsetti, Alessandra ^a   Caputo, Antonella ^b   Vardas, Eftyhia ^d   Colvin, Mark ^e   Lukwiya, Matthew ^f   Rezza, Giovanni ^a   Ensoli, Barbara ^a,g  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^f St Mary's Hospital Lacor Uganda   (Uganda)

^g ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEIN ANTIBODY; TRANSACTIVATOR PROTEIN; VIRUS PROTEIN;

ADOLESCENT; ADULT; ANTIGEN RECOGNITION; ARTICLE; CLADISTICS; EPITOPE MAPPING; FEMALE; GENETIC CONSERVATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENETICS; ITALY; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SOUTH AFRICA; UGANDA; VIRUS INFECTION; VIRUS STRAIN;

ADOLESCENT; ADULT; AIDS VACCINES; AMINO ACID SEQUENCE; CONSERVED SEQUENCE; CROSS REACTIONS; CROSS-SECTIONAL STUDIES; EPITOPE MAPPING; FEMALE; GENE PRODUCTS, TAT; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; ITALY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; SEQUENCE ANALYSIS, DNA; SOUTH AFRICA; UGANDA;

EID: 0242364649     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/378412     Document Type: Article

References (56)

1. Kuiken C, Foley B, Hahn B, et al., eds. HIV sequence compendium 2001. Los Alamos National Laboratory, NM: Theoretical Biology and Biophysics Group, 2001.
2. Burton DR. A vaccine for HIV type 1: the antibody perspective. Proc Natl Acad Sci USA 1997;94:10018-23.
3. Hulskotte EG, Geretti AM, Osterhaus AD. Towards an HIV-1 vaccine: lessons from studies in macaque models. Vaccine 1998; 16:904-15.
4. Buge SL, Murty L, Arora K, et al. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. J Virol 1999; 73:7430-40.
5. Osterhaus AD, van Baalen CA, Gruters RA, et al. Vaccination with Rev and Tat against AIDS. Vaccine 1999; 17:2713-4.
6. Cafaro A, Caputo A, Fracasso C, et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999; 5:643-50.
7. Cafaro A, Caputo A, Maggiorella MT, et al. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J Med Primatol 2000; 29:193-208.
8. Pauza CD, Trivedi P, Wallace M, et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci USA 2000; 97:3515-19.
9. Allen TM, O'Connor DH, Jing P, et al. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407:386-90.
10. Cafaro A, Titti F, Fracasso C, et al. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 2001; 19:2862-77.
11. Barouch DH, Santra S, Kuroda MJ, et al. Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 2001; 75:5151-8.
12. Barouch DH, Fu TM, Montefiori DC, Lewis MG, Shiver JW, Letvin NL. Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. Immunol Lett 2001; 79: 57-61.
13. Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001; 292:69-74.
14. Amara RR, Villinger F, Staprans SI, et al. Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J Virol 2002; 76:7625-31.
15. Wu Y, Marsh JW. Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA. Science 2001; 293:1503-6.
16. Arya SK, Guo C, Josephs SF, Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985; 229:69-73.
17. Fisher AG, Feinberg MB, Josephs SF, et al. The trans-activator gene of HTLV-III is essential for virus replication. Nature 1986; 320:367-71.
18. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55:1189-93.
19. Ensoli B, Barillari G, Salahuddin SZ, Gallo RC, Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990; 345:84-6.
20. Barillari G, Buonaguro L, Fiorelli V, et al. Effects of cytokines from activated immune cells on vascular cell growth and HIV-1 gene expression: implications for AIDS-Kaposi's sarcoma pathogenesis. J Immunol 1992; 149:3727-34.
21. Ensoli B, Buonaguro L, Barillari G, et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67:277-87.
22. Chang HK, Gallo RC, Ensoli B. Regulation of cellular gene expression and function by the human immunodeficiency virus type 1 Tat protein. J Biomed Sci 1995; 2:189-202.
23. Westendorp MO, Frank R, Ochsenbauer C, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375: 497-500.
24. Chang HC, Samaniego F, Nair BC, Buonauguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997; 11:1421-31.
25. Li CJ, Ueda Y, Shi B, et al. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc Natl Acad Sci USA 1997; 94:8116-20.
26. Huang L, Bosch I, Hofmann W, Sodroski J, Pardee AB. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J Virol 1998; 72:8952-60.
27. Reiss P, Lange JM, de Ronde A, et al. Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol 1990; 30:163-8.
28. Froebel KS, Aldhous MC, Mok JY, Hayley J, Arnott M, Peutherer JF. Cytotoxic T lymphocyte activity in children infected with HIV. AIDS Res Hum Retroviruses 1994; 10:S83-8.
29. Re MC, Furlini G, Vignoli M, et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10:408-16.
30. van Baalen CA, Pontesilli O, Huisman RC, et al. Human immunodeficiency virus type 1 Rev-and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997; 78:1913-8.
31. Zagury JF, Sill A, Blattner W, et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol 1998; 1:282-92.
32. Fanales-Belasio E, Moretti S, Nappi F, et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 2002; 168:197-206.
33. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases. Clin Microbiol Rev 1996; 9:532-62.
34. Kimura M. The neutral theory of molecular evolution. Cambridge, UK: Cambridge University Press, 1983.
35. Krone WJ, Debouck C, Epstein LG, Heutink P, Meloen R, Goudsmit J. Natural antibodies to HIV-tat epitopes and expression of HIV-1 genes in vivo. J Med Virol 1988; 26:261-70.
36. Tahtinen M, Ranki A, Valle SL, Ovod V, Krohn K. B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains. Biomed Pharmacother 1997; 51:480-7.
37. Demirhan I, Chandra A, Mueller F, et al. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma. J Hum Virol 2000; 3:137-43.
38. Goldstein G, Tribbick G, Manson K. Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains. Vaccine 2001; 19:1738-46.
39. Balotta C, Facchi G, Violin M, et al. Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir Immune Defic Syndr 2001; 27:499-505.
40. Becker-Pergola G, Mellquist JL, Guay L, et al. Identification of diverse HIV type 1 subtypes and dual HIV type 1 infection in pregnant Ugandan women. AIDS Res Hum Retroviruses 2000; 16:1099-104.
41. Bredell H, Hunt G, Morgan B, Tiemessen CT, Martin DJ, Morris L. Identification of HIV type 1 intersubtype recombinants in South Africa using env and gag heteroduplex mobility assays. AIDS Res Hum Retroviruses 2000; 16:493-7.
42. Bredell H, Hunt G, Casteling A, et al. HIV-1 subtype A, D, G, AG and unclassified sequences identified in South Africa. AIDS Res Hum Retroviruses 2002; 18:681-3.
43. Brennan CA, Lund JK, Golden A, et al. Serologic and phylogenetic characterization of HIV-1 subtypes in Uganda. AIDS 1997; 11:1823-32.
44. Catucci M, Venturi G, Romano L, Valensin PE, Zazzi M. Analysis of the HIV-1 nef gene in five intravenous drug users with long-term nonprogressive HIV-1 infection in Italy. J Med Virol 2000; 60:294-9.
45. Engelbrecht S, de Villiers T, Sampson CC, zur Megede J, Barnett SW, van Rensburg EJ. Genetic analysis of the complete gag and env genes of HIV type 1 subtype C primary isolates from South Africa. AIDS Res Hum Retroviruses 2001; 17:1533-47.
46. Hu DJ, Baggs J, Downing RG, et al. Predominance of HIV-1 subtype A and D infections in Uganda. Emerg Infect Dis 2000; 6:609-15.
47. Kaleebu P, Whitworth J, Hamilton L, et al. Molecular epidemiology of HIV type 1 in a rural community in southwest Uganda. AIDS Res Hum Retroviruses 2000; 16:393-401.
48. van Harmelen J, Williamson C, Kim B, et al. Characterization of full-length HIV type 1 subtype C sequences from South Africa. AIDS Res Hum Retroviruses 2001; 17:1527-31.
49. Addo MM, Altfeld M, Rosenberg ES, et al. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals. Proc Natl Acad Sci USA 2001; 98:1781-6.
50. Novitsky V, Rybak N, McLane MF, et al. Identification of human immunodeficiency virus type 1 subtype C Gag-, Tat-, Rev-, and Nef-specific elispot-based cytotoxic T-lymphocyte responses for AIDS vaccine design. J Virol 2001; 75:9210-28.
51. Novitsky V, Cao H, Rybak N, et al. Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C. J Virol 2002; 76:10155-68.
52. Rappaport J, Lee SJ, Khalili K, Wong-Staal F. The acidic amino-terminal region of the HIV-1 Tat protein constitutes an essential activating domain. New Biol 1989; 1:101-10.
53. Blazevic V, Ranki A, Mattinen S, et al. Helper T-cell recognition of HIV-1 Tat synthetic peptides. J Acquir Immune Defic Syndr 1993; 6:881-90.
54. McPhee DA, Kemp BE, Cumming S, Stapleton D, Gust ID, Doherty RR. Recognition of envelope and tat protein synthetic peptide analogs by HIV positive sera or plasma. FEBS Lett 1988; 233:393-6.
55. Rodman TC, Pruslin FH, To SE, Winston R. Human immunodeficiency virus (HIV) Tat-reactive antibodies present in normal HIV-negative sera and depleted in HIV-positive sera. Identification of the epitope. J Exp Med 1992; 175:1247-53.
56. Ratner L, Haseltine W, Patarca R, et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985; 313:277-84.